| Field | Specification |
|---|---|
| UniProt # | |
| Applications | |
| Sensitivity | |
| Detection range | |
| Detection method | |
| Assay time | |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Scientific Background
This ELISA kit applies to the in vitro quantitative determination of Mouse BNP concentrations in serum, plasma and other biological fluids.
Assay Principle
This ELISA kit uses the Competitive-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with Mouse BNP. During the reaction, Mouse BNP in the sample or standard competes with a fixed amount of Mouse BNP on the solid phase supporter for sites on the Biotinylated Detection Ab specific to Mouse BNP. Excess conjugate and unbound sample or standard are washed away, and Avidin-Horseradish Peroxidase (HRP) conjugate are added to each micro plate well and incubated. Then a TMB substrate solution is added to each well. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns from blue to yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The concentration of Mouse BNP in tested samples can be calculated by comparing the OD of the samples to the standard curve.
Performance Specifications
| Sensitivity | 9.38 pg/mL |
|---|---|
| Detection Range | 15.63-1000 pg/mL |
| Total Assay Time | 2 h 30 min |
| Compatible Sample Types | Serum, plasma and other biological fluids |
| Species Reactivity | Mouse |
| Detection Method | Competitive |
| Precision (CV) | Both intra-CV and inter-CV are < 10%. |
| Recovery Rate | 80%-120% |
| Storage | 2-8℃,12 months |
✓ Research-Grade Validation
Specificity
This kit recognizes Mouse BNP in samples.No significant cross-reactivity or interference between Mouse BNP and analogues was observed
Safety & Regulatory
Handle reagents in accordance with institutional biosafety guidelines. Refer to the Safety Data Sheet (SDS) for complete hazard and handling information. Contains components that may require special disposal procedures per local regulations.
This kit is validated for use with Serum, plasma and other biological fluids. For unlisted matrices (e.g., tissue lysate, urine), perform a spike-and-recovery experiment to confirm assay performance before generating reportable data. Sample dilution in the kit's provided diluent is recommended to minimize matrix interference.
The minimum detectable concentration (sensitivity) of this kit is 9.38 pg/mL. Values below this threshold should be reported as below the limit of detection (<LOD) and should not be extrapolated from the standard curve.
The total assay time from sample addition to absorbance reading is approximately 2 h 30 min, including all incubation, wash, and substrate steps. Hands-on time is typically 1–2 hours; most steps involve passive plate incubation. Plan the assay as a single uninterrupted session for best results.
Standard components of this Competitive ELISA Kit typically include: pre-coated microplate (96-well strip format), lyophilized or liquid recombinant BNP standard, detection antibody, streptavidin-HRP conjugate, TMB substrate, stop solution, wash buffer concentrate, and sample/standard diluent. Refer to the kit insert or datasheet for the exact component list and storage requirements.
This kit uses colorimetric (TMB/HRP) detection and requires a standard microplate absorbance reader capable of measuring at 450 nm. A reference wavelength of 570 nm or 630 nm is recommended to reduce background. No specialized fluorescence or luminescence reader is needed. Ensure the instrument is calibrated and the plate is clean and free of condensation before reading.
Tissue samples may contain endogenous or exogenous proteases during processing, leading to degradation of extracted proteins. Therefore, it's necessary to add protease inhibitors during processing to ensure the integrity of target proteins. If customers can keep samples cold and handle them quickly during processing, omitting the protease inhibitor may not have a significant effect. After preparation, samples should be tested promptly or immediately aliquoted and frozen at -20°C or -80°C.
What is the range of enzyme activity of your IL-2 freeze-dried powder
What is the principle of adding stop solution to stop color reaction in ELISA experiment?
Can’t Find What You’re Looking For? We can help you source the best match or customize an ELISA solution for your study. Options may include alternative target synonyms, different species reactivity, sample type/matrix compatibility (serum/plasma/lysate/supernatant), assay format (sandwich/competitive), sensitivity/range, detection chemistry (colorimetric/fluorescent/chemiluminescent), plate format (pre-coated/uncoated, strips vs full plate), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
Heart failure-induced cognitive dysfunction is mediated by intracellular Ca2+ leak through ryanodine receptor type 2 (2023) NATURE NEUROSCIENCE. 10.1038/s41593-023-01377-6
Bifunctional Peptide-Engineered Mitochondria Alleviate Myocarditis and Cardiac Fibrosis by Site-Specifically Inhibiting NETosis (2025) ADVANCED FUNCTIONAL MATERIALS. 10.1002/adfm.202501018
Compound Danshen Dripping Pill inhibits hypercholesterolemia/atherosclerosis-induced heart failure in ApoE and LDLR dual deficient mice via multiple mechanisms (2022) Acta Pharmaceutica Sinica B. 10.1016/j.apsb.2022.11.012
Moderate-intensity interval exercise exacerbates cardiac lipotoxicity in high-fat, high-calories diet-fed mice (2025) Nature Communications. 10.1038/s41467-025-55917-8
CD248-targeted BBIR-T cell therapy against late-activated fibroblasts in cardiac repair after myocardial infarction (2025) Nature Communications. 10.1038/s41467-025-56703-2
Cardiac Urea Cycle Activation by Time-Restricted Feeding Protects Against Pressure Overload-Induced Heart Failure (2024) Advanced Science. 10.1002/advs.202407677
Targeting Viperin prevents coxsackievirus B3-induced acute heart failure (2025) Cell Discovery. 10.1038/s41421-025-00778-0
Roxadustat improves diabetic myocardial injury by upregulating HIF-1α/UCP2 against oxidative stress (2025) Cardiovascular Diabetology. 10.1186/s12933-025-02601-2
ATP5A1 succinylation as a key driver for the transition of myocardial ischemia to development of heart failure (2026) BASIC RESEARCH IN CARDIOLOGY. 10.1007/s00395-026-01172-x
HPV VLPs-based RNA-delivery system for synergistic BCL-2 silencing and mitochondrial apoptosis in NSCLC cells (2025) MATERIALS & DESIGN. 10.1016/j.matdes.2025.114820
Porcupine inhibitor CGX1321 alleviates heart failure with preserved ejection fraction in mice by blocking WNT signaling (2022) ACTA PHARMACOLOGICA SINICA. 10.1038/s41401-022-01025-y
Compound Danshen Dripping Pill inhibits doxorubicin or isoproterenol-induced cardiotoxicity (2021) BIOMEDICINE & PHARMACOTHERAPY. 10.1016/j.biopha.2021.111531
MCC950 attenuates doxorubicin-induced myocardial injury in vivo and in vitro by inhibiting NLRP3-mediated pyroptosis (2021) BIOMEDICINE & PHARMACOTHERAPY. 10.1016/j.biopha.2021.112133
L-carnitine alleviates cardiac microvascular dysfunction in diabetic cardiomyopathy by enhancing PINK1-Parkin-dependent mitophagy through the CPT1a-PHB2-PARL pathways (2023) Acta Physiologica. 10.1111/apha.13975
sVEGFR3 alleviates myocardial ischemia/reperfusion injury through regulating mitochondrial homeostasis and immune cell infiltration (2025) APOPTOSIS. 10.1007/s10495-024-02068-8
Deletion of MAPL ameliorates septic cardiomyopathy by mitigating mitochondrial dysfunction (2024) Journal of Translational Medicine. 10.1186/s12967-024-05836-x
Combining multi-omics analysis methods to identify biomarkers for mitophagy involved in immune checkpoint inhibitors-related myocarditis (2026) Frontiers in Immunology. 10.3389/fimmu.2026.1691848
Role of the Gut Microbiota in Glucose Metabolism During Heart Failure (2022) Frontiers in Cardiovascular Medicine. 10.3389/fcvm.2022.903316
Astragalus propinquus schischkin and Salvia miltiorrhiza bunge promote angiogenesis to treat myocardial ischemia via Ang-1/Tie-2/FAK pathway (2023) Frontiers in Pharmacology. 10.3389/fphar.2022.1103557
microRNA-193-3p attenuates myocardial injury of mice with sepsis via STAT3/HMGB1 axis (2021) Journal of Translational Medicine. 10.1186/s12967-021-03022-x
Recombinant Soluble Corin Improves Cardiac Function in Mouse Models of Heart Failure (2021) Journal of the American Heart Association. 10.1161/JAHA.120.019961
SARS-CoV-2 spike-induced syncytia are senescent and contribute to exacerbated heart failure (2024) PLoS Pathogens. 10.1371/journal.ppat.1012291
Integrated network pharmacology to investigate the mechanism of Salvia miltiorrhiza Bunge in the treatment of myocardial infarction (2023) JOURNAL OF CELLULAR AND MOLECULAR MEDICINE. 10.1111/jcmm.17932
LncRNA HOX transcript antisense RNA mitigates cardiac function injury in chronic heart failure via regulating microRNA-30a-5p to target KDM3A (2022) JOURNAL OF CELLULAR AND MOLECULAR MEDICINE. 10.1111/jcmm.17160
Long-Term Sleep Deprivation-Induced Myocardial Remodeling and Mitochondrial Dysfunction in Mice Were Attenuated by Lipoic Acid and N-Acetylcysteine (2022) Pharmaceuticals. 10.3390/ph16010051
